SAN MATEO, Calif. and SINGAPORE, May 07, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to ...
14d
Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT® in Brain Cancer
Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS) today announced the successful and safe dosing of the first patient in the Phase 1 trial using uTREAT in brain cancer (high grade gliomas).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback